Guardant Health, Inc.GH

時価総額

$127.3億

PER

精密腫瘍学検査の最大手。血液と組織を用いた高感度リキッドバイオプシープラットフォームを展開。2023年5月の公募で381.4百万ドルを調達、2022年6月に合弁持分を177.8百万ドルで買収。米国・欧州・アジア中心に展開。

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-84	-68	-246	-385	-655	-479	-436
Depreciation and amortization	7	11	16	22	36	43	42
Operating lease costs	-	-	6	25	29	30	31
Contingent consideration	-	0	-0	2	4	0	1
Stock-based compensation	7	17	144	151	95	91	140
Amortization of debt issuance costs	-	-	-	-	-	3	3
Amortization of (discount) premium on marketable debt securities	0	2	-4	-13	-5	14	7
Unrealized and realized losses (gains) on marketable equity securities	-	-	-	-	-	-	-44
Other Asset Impairment Charges	-	-	-	-	5	29	-
Other	-	-	-7	-0	-0	1	-2
Accounts receivable, net	23	7	5	44	-0	-8	21
Inventory, net	2	6	8	8	21	10	9
Prepaid expenses and other current assets, net	4	6	6	36	-20	4	8
Other assets, net	0	3	19	4	-12	-1	2
Accounts payable and accrued liabilities	-	-	-	-	60	89	-3
Operating lease liabilities	-	-	-	-	-	-31	-36
Deferred revenue	-	-	-	-	-	2	19
Net cash used in operating activities	-72	-47	-104	-209	-309	-325	-240
Purchases of marketable debt securities	-	-	-	-	-	630	307
Maturities of marketable debt securities	-	-	-	-	-	1,495	35
Proceeds from Sale of Held-to-Maturity Securities	-	-	-	-	-	-	54
Purchases of non-marketable equity securities and other related assets	-	-	-	39	24	6	8
Purchases of property and equipment	20	19	36	75	77	20	35
Net cash (used in) provided by investing activities	-153	-318	-617	-63	150	840	-261
Proceeds from Stock Plans	-	-	-	-	-	10	12
Proceeds from Stock Options Exercised	3	12	10	8	3	0	3
Employee taxes paid related to settlement of restricted stock units	-	-	3	84	8	11	16
Proceeds from equity offerings	-	350	356	-	-	493	-
Payment of equity offering costs	4	1	1	-	-	21	-
Joint Venture Acquisition	-	-	-	-	178	-	-
Noncash, Tender Offer Issued	-	-	-	-	-14	-	-
Other	-	-	-	-	-	6	-0
Net cash (used in) provided by financing activities	293	367	1,410	-67	-189	477	-1
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	-	0	0	-2	-2	-1	-2
Net (decrease) increase in cash, cash equivalents and restricted cash	-	3	690	-341	-350	992	-504
Income Taxes Paid, Net	0	0	0	0	1	2	1
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	17	13	171	4	5	8
Capital Expenditures Incurred but Not yet Paid	-	-	-	-	-	5	4